In the ever-evolving cell therapy landscape, the challenge of potency assay development remains critical. With the field anticipating finalized regulatory guidelines from the FDA, the need to link mechanisms of action to potency assays scientifically has never been more urgent.

At the 4th Cell Therapy Potency Assay Summit, we united analytical development, quality control, and regulatory experts to tackle these pressing issues. Our goal was to collaboratively design robust potency assays that not only conform to changing guidelines but also streamline patient access to the next generation of cell therapies.

Whether you are preparing for your first IND or gearing up for BLA submission, in 2026 this summit will offer you an unparalleled opportunity to gain insights from leading organizations like Arsenal Biosciences, BlueRock Therapeutics, the NIST and Vertex Pharmaceuticals.

Join us next year to equip your team with the industry and academic insights needed to develop practical and reproducible assays, providing a deeper understanding of your cell therapy products for autologous and allogeneic therapies across various cell types and indications.